These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20546830)
41. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Good MF; Pandey M; Batzloff MR; Tyrrell GJ Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214 [TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629 [TBL] [Abstract][Full Text] [Related]
44. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ mBio; 2016 Jun; 7(3):. PubMed ID: 27302756 [TBL] [Abstract][Full Text] [Related]
45. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage. Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249 [TBL] [Abstract][Full Text] [Related]
46. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817 [TBL] [Abstract][Full Text] [Related]
47. Intranasal immunisation of mice with a streptococcal peptide-based vaccine. Relf W; Hayman W; Russell-Jones G; Good M Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788 [No Abstract] [Full Text] [Related]
48. Demonstration of protection in mice from a lethal challenge of three M serotypes of Streptococcus pyogenes using an M-negative vaccine. Chappell JD; Stuart JG Vaccine; 1993; 11(6):643-8. PubMed ID: 8322487 [TBL] [Abstract][Full Text] [Related]
49. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection. Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423 [TBL] [Abstract][Full Text] [Related]
50. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS. Smeesters PR; Dramaix M; Van Melderen L Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033 [No Abstract] [Full Text] [Related]
51. Group A streptococcus epidemiology and vaccine implications. Cohen-Poradosu R; Kasper DL Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050 [No Abstract] [Full Text] [Related]
52. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis. Fischetti VA Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31111819 [TBL] [Abstract][Full Text] [Related]
53. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Dale JB; Penfound T; Chiang EY; Long V; Shulman ST; Beall B Clin Diagn Lab Immunol; 2005 Jul; 12(7):833-6. PubMed ID: 16002631 [TBL] [Abstract][Full Text] [Related]
54. Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity. Frost HR; Laho D; Sanderson-Smith ML; Licciardi P; Donath S; Curtis N; Kado J; Dale JB; Steer AC; Smeesters PR Clin Infect Dis; 2017 Oct; 65(9):1523-1531. PubMed ID: 29020160 [TBL] [Abstract][Full Text] [Related]
55. Antibody levels to the class I and II epitopes of the M protein and myosin are related to group A streptococcal exposure in endemic populations. Brandt ER; Yarwood PJ; McMillan DJ; Vohra H; Currie B; Mammo L; Pruksakorn S; Saour J; Good MF Int Immunol; 2001 Oct; 13(10):1335-43. PubMed ID: 11581178 [TBL] [Abstract][Full Text] [Related]
56. Protective immunogenicity of group A streptococcal M-related proteins. Dale JB; Niedermeyer SE; Agbaosi T; Hysmith ND; Penfound TA; Hohn CM; Pullen M; Bright MI; Murrell DS; Shenep LE; Courtney HS Clin Vaccine Immunol; 2015 Mar; 22(3):344-50. PubMed ID: 25630406 [TBL] [Abstract][Full Text] [Related]
57. Group A streptococcal vaccines: facts versus fantasy. Steer AC; Batzloff MR; Mulholland K; Carapetis JR Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947 [TBL] [Abstract][Full Text] [Related]
58. Recombinant tetravalent group A streptococcal M protein vaccine. Dale JB; Chiang EY; Lederer JW J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202 [TBL] [Abstract][Full Text] [Related]
59. Group A streptococcal antigens and vaccine potential. Kehoe MA Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063 [TBL] [Abstract][Full Text] [Related]
60. Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice. Pandey M; Calcutt A; Ozberk V; Chen Z; Croxen M; Powell J; Langshaw E; Mills JL; Jen FE; McCluskey J; Robson J; Tyrrell GJ; Good MF Sci Adv; 2019 Sep; 5(9):eaax3013. PubMed ID: 31517054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]